JESS ROPER - Corporate Board Profile

BIOLASE, INC

Filing Date	Source Excerpt
2018-08-24	Jess Roper
2019-04-10	Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc., where he held executive leadership positions from 2005 until retiring in April 2017. ... Drs. Lanman and Lord and Messrs. Roper and Sato are members of the Audit Committee and Drs. Lanman, Lord and Wagner and Mr. Sato are members of the Compensation Committee and the Nominating and Corporate Governance Committee. ... The following table sets forth all compensation earned or paid to our non-employee directors during the year ended December 31, 2018. ... Jess Roper ... $104,166.
2020-04-23	Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc. ... The following table sets forth all compensation earned or paid to our non-employee directors during the year ended December 31, 2019. Jess Roper 104,166
2020-12-11	The following table sets forth the beneficial ownership of shares of our common stock as of December 10, 2020 by (i) each current director ... Jess Roper(1) ... Director
2021-04-19	Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc.... Mr. Roper brings to our Board business and operational experience, including capital markets experience. Total compensation: 124,823.
2021-10-08	Listed as a Director in the beneficial ownership table.
2022-03-30	Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc., where he held executive leadership positions from 2005 until retiring in April 2017. DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. While at DexCom, Inc., Mr. Roper also served as its Vice President and Chief Financial Officer and as the Director of Finance. During his tenure, DexCom, Inc. transitioned from a pre-revenue privately held medical device company to a multi-national, publicly traded entity. Mr. Roper previously held financial management positions with two other publicly traded companies and one venture-funded company. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper has a Master of Science degree in Corporate Accountancy and a Bachelor of Science degree in Business Administration in Finance from San Diego State University. He is a Certified Public Accountant and member of the Corporate Directors Forum. Mr. Roper brings to our Board business and operational experience, including capital markets experience.
2023-03-29	Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc., where he held executive leadership positions from 2005 until retiring in April 2017. DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. Mr. Roper brings to our Board business and operational experience, including capital markets experience. The Audit Committee currently consists of Drs. Lord, O’Loughlin, Yale, and Mr. Roper. Mr. Roper serves as its Chairperson. The Nominating and Corporate Governance Committee currently consists of Drs. Lord, O’Loughlin, Somerman, Summerhays, Yale, and Mr. Roper.

Data sourced from SEC filings. Last updated: 2025-12-07